ACE Reno Pico Cell Matrix for reducing proteinuria and supporting kidney function

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, single-arm study giving ACE Reno (1 mL sublingually four times daily) for 12 weeks with a 4-week safety follow-up. The main measure is change in urinary albumin-to-creatinine ratio (ACR) at 12 weeks, with secondary measures including eGFR slope, proteinuria, blood pressure, and patient-reported outcomes. The trial enrolls adults with nephropathy across a range of causes and CKD stages (including post-transplant proteinuria) while allowing stable background therapies such as ACEi/ARB and SGLT2i. Exploratory biomarker analyses (e.g., TGF-β, NGAL, KIM-1, cGMP) and durability of response up to 6 months in responders will also be collected.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults (≥18 years) with nephropathy of any degree (microalbuminuria, overt proteinuria, CKD stages 1-5 not on dialysis, or post-transplant with proteinuria). Stable background therapy with ACEi/ARB, SGLT2i, or MRA allowed.

Exclusion Criteria:

* Recent kidney transplant (\<12 months). Uncontrolled acute infection or unstable autoimmune disease. Pregnancy or lactation. Known hypersensitivity to study components.

Where it's running

• British Centre For Regenerative medicine BCRMED Global
  Giza, Gz, Egypt Recruiting

Study contacts

• Principal investigator: Prof. Dr. Mohammed Yasser Sayyed Saif, PhD — Beni Suef Univeristy
• Study coordinator: Dr. Alaa Abdelkarim M Fouad, MRCPUK SEC
• Email: dralaa@ace-cells.co.uk
• Phone: +447473922553

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Herbal Medicine Use in CKD Patients on Réunion Island

  This study tests how common herbal medicine use is among adults with chronic kidney disease (stages 3–5) on Réunion Island and whether it relates to kidney disease progression over a year.

  Recruiting at 4 sites Centre Hospitalier Universitaire de la Réunion · Saint-Benoît and 3 other locations · NCT07444515

• Observational look at how Kremezin works in adults with advanced chronic kidney disease

  This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.

  Recruiting HK inno.N Corporation · Seoul · NCT07930169

• Synbiotic Therapy for Kidney Function in CKD Stage III-IV

  This study tests whether a synbiotic (probiotics plus prebiotics) can improve kidney function in adults with non-dialysis CKD stage 3-4 compared with a placebo.

  Recruiting Chittagong Medical College · Chittagong · NCT07912359

• Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China

  This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.

  Recruiting Phase 4 Novo Nordisk A/S · Fuyang, Anhui and 25 other locations · NCT07900438

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.